A functional dynamic scoring model to elucidate the significanceof post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with hodgkin's lymphoma

Haematologica

Volumn 95, Issue 7, 2010, Pages 1198-1206

  Dann, Eldad J ^a,c   Bar Shalom, Rachel ^a,c   Tamir, Ada ^c   Epelbaum, Ron ^a,c   Avivi, Irit ^a,c   Ben Shachar, Menachem ^a   Gaitini, Diana ^b   Rowe, Jacob M ^a,c  

^a Department of Hematology and Bone Marrow Transplantation ^*  (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Dynamic score; F18FDG PET; FDG PET CT; Hodgkin's lymphoma; Prognostic factors; Specificity

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

COMPUTER ASSISTED TOMOGRAPHY; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MEDIASTINUM; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ADOLESCENT; ADULT; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; SCINTISCANNING; YOUNG ADULT;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77954473102     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.016105     Document Type: Review

References (21)

1. Gallamini A Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24): 3746-52.
2. Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: what is the evidence base? Nucl Med Commun. 2007;28(5):335-54.
3. Hutchings M, Mikhaeel NG, Fields PA, NunanT, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160-8.
4. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-9.
5. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxy glucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009; 27(11):1906-14.
6. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009:50(8):1257-60.
7. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-8.
8. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-86.
9. Gallamini A. The prognostic role of positron emission tomography scan in Hodgkin's lymphoma. Hematology Education: The Education Program for the Annual Congress of the European Hematology Association. 2009;3:144-50.
10. Dann EJ, Bar-Shalom R, Tamir A, Haim N, Ben-Shachar M, Avivi I, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007; 109(3):905-9.
11. HasencleverDsub7/sub Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-14.
12. Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24(19):3128-35.
13. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91(4):475-81.
15. Andre M RJ, van der Maazen RW, Reman O, van't Veer M, Lutgenburg E, Girinski T, et al. The H10 EORTC/GELA randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma. Haematologica. 2007;92:P7.
16. Johnson P FM, Enblad G, Burton C, Smith P, Qian W, O'Doherty M, Radford J. Response-adapted therapy using FDG-PET scanning after initial ABVD: the UK NCRI, Italian and Nordic trial in advanced Hodgkin lymphoma. Haematologica. 2007;92:P7.
17. Avigdor A BS, Dann E, Levi I, Perez-Avraham G, Shemtov N, Shimoni A, et al. Combined escalated BEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: an effective regimen and low positive predictive value of early FDG-PET/CT Haematologica. 2007, 92:P 66.
18. Mark ova J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plutschow A, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol. 2009;20(7):1270-4.
19. Gallamini A, Bonfante V, Levis A, Di Raimondo F, Merli F, Vitolo U, et al. Early interim FDG-PET during intensified BEACOPP therapy shows a lower predictive value than during conventional ABVD chemotherapy. Haematologica. 2007;92(Suppl 2):144.
20. Meignan M, Itti E, Bardet S, Lumbroso J, Edeline V, Olivier P, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27(16):2739-41.
21. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47(6):1059-66.